CN105431452B - 中和IL-1β的人单克隆抗体 - Google Patents

中和IL-1β的人单克隆抗体 Download PDF

Info

Publication number
CN105431452B
CN105431452B CN201380019370.3A CN201380019370A CN105431452B CN 105431452 B CN105431452 B CN 105431452B CN 201380019370 A CN201380019370 A CN 201380019370A CN 105431452 B CN105431452 B CN 105431452B
Authority
CN
China
Prior art keywords
isolated
specific antibody
antibody
seq
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380019370.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN105431452A (zh
Inventor
汪正一
吴喜华
杨淑斌
阿莱桑德拉·莫特拉罗
苏博哈拉·库玛尔·比斯瓦斯
佛罗伦特·吉恩欧克斯
钟平宇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science Technology and Research Singapore
Original Assignee
Agency for Science Technology and Research Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science Technology and Research Singapore filed Critical Agency for Science Technology and Research Singapore
Publication of CN105431452A publication Critical patent/CN105431452A/zh
Application granted granted Critical
Publication of CN105431452B publication Critical patent/CN105431452B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201380019370.3A 2012-02-13 2013-02-13 中和IL-1β的人单克隆抗体 Active CN105431452B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG201201007-0 2012-02-13
SG2012010070 2012-02-13
PCT/SG2013/000057 WO2013122544A2 (en) 2012-02-13 2013-02-13 IL-1β NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES

Publications (2)

Publication Number Publication Date
CN105431452A CN105431452A (zh) 2016-03-23
CN105431452B true CN105431452B (zh) 2019-12-31

Family

ID=54261183

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380019370.3A Active CN105431452B (zh) 2012-02-13 2013-02-13 中和IL-1β的人单克隆抗体

Country Status (17)

Country Link
US (5) US10167335B2 (enExample)
EP (2) EP3736289A1 (enExample)
JP (1) JP6383665B2 (enExample)
CN (1) CN105431452B (enExample)
CY (1) CY1123519T1 (enExample)
DK (1) DK2814843T3 (enExample)
ES (1) ES2798110T3 (enExample)
HR (1) HRP20200964T1 (enExample)
HU (1) HUE049860T2 (enExample)
LT (1) LT2814843T (enExample)
PL (1) PL2814843T3 (enExample)
PT (1) PT2814843T (enExample)
RS (1) RS60583B1 (enExample)
SG (2) SG10201708562VA (enExample)
SI (1) SI2814843T1 (enExample)
SM (1) SMT202000321T1 (enExample)
WO (1) WO2013122544A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2814843T (pt) 2012-02-13 2020-06-18 Agency Science Tech & Res Anticorpos monoclonais humanos neutralizantes de il-b
CN106928354B (zh) * 2017-04-25 2020-07-17 长春金赛药业有限责任公司 抗IL-1β单克隆抗体及其应用
TW201904993A (zh) * 2017-06-22 2019-02-01 瑞士商諾華公司 IL-1β 結合抗體之用途
CN117024587A (zh) * 2019-03-07 2023-11-10 瑞阳(苏州)生物科技有限公司 人IL-1β蛋白结合分子及其编码基因和应用
KR102087743B1 (ko) * 2019-06-10 2020-03-12 을지대학교 산학협력단 IL-1beta에 특이적으로 결합하는 항체 및 그의 용도
WO2025006936A2 (en) * 2023-06-29 2025-01-02 University Of Maine System Board Of Trustees Methods and compositions for fire-fighting
WO2025147459A1 (en) 2024-01-04 2025-07-10 Nano Precision Medical, Inc. Stabilization of peptides and proteins in implantable devices and formulations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101228188A (zh) * 2005-06-21 2008-07-23 佐马技术有限公司 IL-1β结合抗体及其片段
CN101472949A (zh) * 2006-04-24 2009-07-01 安姆根有限公司 人源化c-Kit抗体

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
CZ1497A3 (en) 1994-07-05 1997-05-14 Steeno Res Group As Polypeptide, its use and pharmaceutical composition based thereon, a nucleotide sequence and antibody
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US20030007972A1 (en) 1999-02-24 2003-01-09 Edward Tobinick Cytokine antagonists and other biologics for the treatment of bone metastases
GB0001448D0 (en) 2000-01-21 2000-03-08 Novartis Ag Organic compounds
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
JP5291279B2 (ja) 2000-09-08 2013-09-18 ウニヴェルジテート・チューリッヒ 反復モジュールを含む反復タンパク質の集合体
CA2509136C (en) 2003-01-24 2013-10-29 Applied Molecular Evolution, Inc. Human il-1 beta antagonists
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
AU2004253835B2 (en) 2003-07-04 2009-01-29 Affibody Ab Polypeptides having binding affinity for HER2
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
BRPI0417302A (pt) 2003-12-05 2007-03-06 Compound Therapeutics Inc inibidores de receptores de fator de crescimento endotelial vascular do tipo 2
WO2006081139A2 (en) * 2005-01-26 2006-08-03 Abgenix, Inc. Antibodies against interleukin-1 beta
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety
UY32949A (es) 2009-10-15 2011-02-28 Abbott Lab Proteínas de unión a il-1
WO2012121679A1 (en) 2011-03-09 2012-09-13 Agency For Science, Technology And Research Method of modulating phenotype of a renal cell cancer-associated monocyte or macrophage
TWI671315B (zh) * 2011-03-28 2019-09-11 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
PT2814843T (pt) 2012-02-13 2020-06-18 Agency Science Tech & Res Anticorpos monoclonais humanos neutralizantes de il-b
WO2016008851A1 (en) 2014-07-14 2016-01-21 Boehringer Ingelheim International Gmbh Anti-il-1b antibodies
WO2016183176A1 (en) 2015-05-12 2016-11-17 Drexel University Compounds and compositions useful for treating or preventing cancer metastasis, and methods using same
WO2017019896A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to pd-1
US10397741B2 (en) 2016-11-11 2019-08-27 Shoreline Tracking Systems, LLC System and method for service tracking
TW201904993A (zh) 2017-06-22 2019-02-01 瑞士商諾華公司 IL-1β 結合抗體之用途
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
WO2020039401A1 (en) 2018-08-24 2020-02-27 Novartis Ag Treatment comprising il-1βeta binding antibodies and combinations thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101228188A (zh) * 2005-06-21 2008-07-23 佐马技术有限公司 IL-1β结合抗体及其片段
CN101472949A (zh) * 2006-04-24 2009-07-01 安姆根有限公司 人源化c-Kit抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Treatment with an interleukin 1 beta antibody improves glycemic control in diet induced obesity.;O Osborn等;《cytokine》;20081231;第44卷(第1期);全文 *

Also Published As

Publication number Publication date
US20150037248A1 (en) 2015-02-05
US11912761B2 (en) 2024-02-27
WO2013122544A2 (en) 2013-08-22
US20190144535A1 (en) 2019-05-16
US10919962B2 (en) 2021-02-16
DK2814843T3 (da) 2020-06-22
US20210155686A1 (en) 2021-05-27
EP2814843B1 (en) 2020-03-18
WO2013122544A9 (en) 2014-10-02
JP6383665B2 (ja) 2018-08-29
LT2814843T (lt) 2020-09-25
EP2814843A4 (en) 2016-04-06
SG10201708562VA (en) 2017-12-28
SG11201404850SA (en) 2014-09-26
PL2814843T3 (pl) 2020-11-16
SI2814843T1 (sl) 2020-11-30
US20210155685A1 (en) 2021-05-27
WO2013122544A3 (en) 2015-03-26
ES2798110T3 (es) 2020-12-09
CY1123519T1 (el) 2022-03-24
HUE049860T2 (hu) 2020-11-30
US11702471B2 (en) 2023-07-18
CN105431452A (zh) 2016-03-23
RS60583B1 (sr) 2020-08-31
US10167335B2 (en) 2019-01-01
HRP20200964T1 (hr) 2020-10-30
PT2814843T (pt) 2020-06-18
JP2015518368A (ja) 2015-07-02
US11780913B2 (en) 2023-10-10
SMT202000321T1 (it) 2020-07-08
EP3736289A1 (en) 2020-11-11
US20210024627A1 (en) 2021-01-28
EP2814843A2 (en) 2014-12-24

Similar Documents

Publication Publication Date Title
US11702471B2 (en) IL-1β neutralizing human monoclonal antibodies
TWI674274B (zh) 抗體－飛諾莫接合物
AU2016239858B2 (en) Antibodies to canine interleukin-4 receptor alpha
EP2970448B1 (en) Human antibodies to grem 1
CN102574923B (zh) 针对人蛋白酶激活受体-2的高亲和力人抗体
KR20200139725A (ko) Her3 항원 결합 분자
KR20170068458A (ko) 항-ｎｋｇ2ａ 항체를 사용한 치료 요법
KR20160131061A (ko) 항-mcam 항체 및 관련된 사용 방법
EP3416983A1 (en) Antibodies for il-17c
CN119365488A (zh) 抗bdca2抗体及其用途
JP2022534514A (ja) Ａｌｋ７結合タンパク質及びその使用
IL310427A (en) Pharmaceutical composition of anti-il4r antibody and use thereof
KR20250153216A (ko) Fap/cd40 결합 분자의 약학적 조성물 및 이의 의약적 용도
KR20240049304A (ko) 융합 단백질을 함유하는 약학적 조성물
HK40041071A (en) Il-beta neutralizing human monoclonal antibodies
JP7643727B2 (ja) 抗－ｆｇｆ１９抗体
CN113166264B (zh) 一种分离的抗原结合蛋白及其用途
TW202448933A (zh) 用抗轉化生長因子β３抗體治療ＴＧＦβ相關病症之方法
JP2017057201A (ja) 抗体−フィノマー複合体を含む医薬組成物
WO2025051889A1 (en) Anti pd-l2 antibodies for use in treating fibrotic diseases
WO2024188331A1 (zh) 一种含pd-1/pvrig/tigit结合蛋白的药物组合物及其医药用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant